Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder that leads to progressive mental, behavioral, and functional decline including learning ability. The extracellular deposition of amyloid-β (Aβ) peptide as diffused and neuritic plaques and hyper-phosphorylation of tau (p-tau) protein accumulated intracellularly as neurofibrillary tangles (NFTs) are considered to be the major pathological hallmarks occurring in the AD brain. Designing of drugs hitting more than one target against multifactorial diseases, like AD, is one of the worthwhile approach in the drug discovery. Identifying the compounds with computer-aided drug design (CADD) significantly saves the limited resources and accelerates the drug development cycles. The enzymes, BACE-1 and GSK-3β are involved in the initiation of Aβ production through the cleavage of extracellular domain of APP and phosphorylation of various substrates, respectively, leading to the cognitive deficiencies in AD. Thus, targeting BACE-1 and GSK-3β involved in distinct pathological conditions, with single inhibitor, could be conducive approach. In this study, combined structure and ligand-based in silico approach were used to identify potential dual targeting inhibitors. The structure and pharmacophore-based virtual screening, homology modeling, molecular docking, drug-likeness, ADME properties prediction, toxicity risk assessment analysis and molecular dynamics studies were performed to obtain the potential inhibitors. The identified dual inhibitors, i.e., ZINC225531247 and ZINC668197980, are expected to be good leads against BACE-1 and GSK-3β.
Graphical abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bajad NG, Rayala S, Gutti G, Sharma A, Singh M, Kumar A et al (2021) Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. Curr Res Pharmacol Drug Discov 2:100026
Basha SJ, Mohan P, Yeggoni DP, Babu ZR, Kumar PB, Rao AD et al (2018) New flavone-cyanoacetamide hybrids with a combination of cholinergic, antioxidant, modulation of β-amyloid aggregation, and neuroprotection properties as innovative multifunctional therapeutic candidates for Alzheimer’s disease and unraveling their mechanism of action with acetylcholinesterase. Mol Pharm 15(6):2206–2223
Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, Nilsson Y et al (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278(46):45937–45945
Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T et al (2014) SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42(W1):W252–W258
Bussi G, Zykova-Timan T, Parrinello M (2009) Isothermal-isobaric molecular dynamics using stochastic velocity rescaling. J Chem Phys 130(7):074101
Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M et al (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51(3):347–372
Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM et al (2011) β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 25(2):775–784
Coimbra JR, Marques DF, Baptista SJ, Pereira CM, Moreira PI, Dinis TC et al (2018) Highlights in BACE1 inhibitors for Alzheimer’s disease treatment. Front Chem 6:178
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K et al (2019) Alzheimer’s disease drug development pipeline. Alzheimer’s Dement: Trans Research Clin Interv 5:272–293
Daina A, Michielin O, Zoete V (2017) Swiss ADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7(1):1–13
De Simone A, Tumiatti V, Andrisano V, Milelli A (2020) Glycogen synthase kinase 3β: a new gold rush in anti-Alzheimer’s disease multitarget drug discovery? Miniperspective J Med Chem 64(1):26–41
Egan WJ, Merz KM et al (2000) Prediction of drug absorption using multivariate statistics. J Med Chem 43(21):3867–3877
Elangovan ND, Dhanabalan AK, Gunasekaran K, Kandimalla R, Sankarganesh DJ (2021) Dynamics. Screening of potential drug for Alzheimer’s disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation. J Biomole Struct Dyn 39(18):7065–79
Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103(19):8577–8593
Ganeshpurkar A, Singh R, Gore PG, Kumar D, Gutti G, Kumar A et al (2020) Structure-based screening and molecular dynamics simulation studies for the identification of potential acetylcholinesterase inhibitors. Mol Simul 46(3):169–185
Gentles RG, Hu S, Dubowchik GM (2009) Chapter 1 recent advances in the discovery of GSK-3 inhibitors and a perspective on their utility for the treatment of Alzheimer’s disease. Annual reports in medicinal chemistry volume, vol 44. Elsevier, pp 3–26
Ghose AK, Viswanadhan VN, Wendoloski J (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1(1):55–68
Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni S, Xu X, Miller HB et al (2008) Potent memapsin 2 (β-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 18(3):1031–1036
Goddard TD, Huang CC et al (2007) Visualizing density maps with UCSF Chimera. J Struct Biol 157(1):281–287
Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW et al (2009) Validation of molecular docking programs for virtual screening against dihydropteroate synthase. J Chem Inf Model 49(2):444–460
Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI (2012) Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther 136(1):8–22
Hong L, Turner RT, Koelsch G, Shin D, Ghosh AK, Tang J (2002) Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00-3. Biochemistry 41(36):10963–10967
Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem 104(6):1433–1439
Kirchdoerfer RN, Ward AB (2019) Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 10(1):1–9
Kumar A, Sharma A (2018) Computational modeling of multi-target-directed inhibitors against Alzheimer’s disease. Computational modeling of drugs against Alzheimer’s disease: Springer p. 533-71
Kumar A, Singh AJ (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Reports 67(2):195–203
Lee S, Park S, Lee I, No KJK. (2007) PreAD-MET Ver. v2. 0, BMDRC: Seoul
Lipinski CA (2004) Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today: Technol 1(4):337–341
Llorens-Marítin M, Jurado J, Hernández F, Ávila J (2014) GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 7:46
Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A et al (2012) Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123(1):224–235
MacKerell AD Jr, Bashford D, Bellott M, Dunbrack RL Jr, Evanseck JD, Field MJ et al (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102(18):3586–3616
Martinez A, Gil C, Perez DI (2011) Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer’s disease treatment. Int J Alzheimer’s Dis 2011:1–7
Martyna GJ, Tobias DJ, Klein ML (1994) Constant pressure molecular dynamics algorithms. J Chem Phys 101(5):4177–4189
Muegge I, Heald SL et al (2001) Simple selection criteria for drug-like chemical matter. J Med Chem 44(12):1841–1846
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera? A visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612
Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88(4):640–651
Roy K, Kar S, Das RN. (2015) Understanding the basics of QSAR for applications in pharmaceutical sciences and risk assessment: Academic press
Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein–ligand interaction profiler. Nucleic Acids Res 43(W1):W443–W447
Salo-Ahen OM, Alanko I, Bhadane R, Bonvin AM, Honorato RV, Hossain S et al (2021) Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes 9(1):71
Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG (2019) Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog Neurobiol 174:53–89
Studio DJSD, CA, USA. Accelrys Inc. (2013)
Sunseri J, Koes DR (2016) Pharmit: interactive exploration of chemical space. Nucleic Acids Res 44(W1):W442–W448
ul Islam B, Tabrez S (2017) Management of Alzheimer’s disease—an insight of the enzymatic and other novel potential targets. Int J Biol Macromol 97:700–709
Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW (2002) Kopple Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615–2623
Wei D, Jiang X, Zhou L, Chen J, Chen Z, He C et al (2008) Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem 51(24):7882–7888
Yan R, Vassar R (2014) Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neuro 13(3):319–329
Yang SY (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15(11–12):444–450
Yang ZR, Chou KC (2004) Bio-support vector machines for computational proteomics. Bioinformatics 20(5):735–741
Zeng H, Wu X (2016) Alzheimer’s disease drug development based on computer-aided drug design. Eur Jurnal Med Chem 121:851–863
Acknowledgements
Ravi Bhushan Singh would like to thank DST, SERB, New Delhi, for the award of TARE grant to him. NGB, RS, RS, AG, and GG thank Ministry of Education (MoE), New Delhi, India, for the teaching assistantship to them. The resources and support provided by the ‘PARAM Shivay Facility’ under the National Supercomputing Mission, Government of India, at the Indian Institute of Technology (BHU), Varanasi, are gratefully acknowledged. We would also like to acknowledge the computational support received from Centre for Computing and Information Services (CCIS), Indian Institute of Technology (BHU), Varanasi.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bajad, N.G., Swetha, R., Singh, R. et al. Combined structure and ligand-based design of dual BACE-1/GSK-3β inhibitors for Alzheimer’s disease. Chem. Pap. 76, 7507–7524 (2022). https://doi.org/10.1007/s11696-022-02421-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11696-022-02421-8